Table 1.
Baseline characteristics of patients with metastatic urothelial carcinoma who participated in this study
| Characteristic | n | % |
|---|---|---|
| No. of patients | 45 | — |
| Median age, years (range) | 68 (35–78) | — |
| Male:female | 32:13 | — |
| ECOG performance status | ||
| 0 | 35 | 77.8 |
| 1 | 6 | 13.3 |
| 2 | 4 | 8.9 |
| Primary site | ||
| Bladder | 26 | 57.7 |
| Renal pelvis | 13 | 28.9 |
| Ureter | 6 | 13.3 |
| Metastatic sites | ||
| Lymph nodes | 31 | 68.9 |
| Pelvic mass | 5 | 11.1 |
| Lung | 15 | 33.3 |
| Liver | 9 | 20.0 |
| Bone | 6 | 13.3 |
| Adrenal | 1 | 2.2 |
| Ovary | 1 | 2.2 |
| Duodenum | 1 | 2.2 |
| Peritoneum | 1 | 2.2 |
| Contralateral renal pelvis | 1 | 2.2 |
| No. of sites with tumor involvement | ||
| 1 | 25 | 55.6 |
| 2 | 14 | 31.1 |
| ≥3 | 6 | 13.3 |
| Prior chemotherapy | ||
| MVAC | 35 | 77.8 |
| GC | 10 | 22.2 |
—, Not applicable; ECOG, Eastern Cooperative Oncology Group; GC, gemcitabine and cisplatin; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin.